Cargando…

N-truncated Aβ(4–x) peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

BACKGROUND: The deposition of neurotoxic amyloid-β (Aβ) peptides in plaques in the brain parenchyma and in cerebral blood vessels is considered to be a key event in Alzheimer’s disease (AD) pathogenesis. Although the presence and impact of full-length Aβ peptides such as Aβ(1–40) and Aβ(1–42) have b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wirths, Oliver, Walter, Susanne, Kraus, Inga, Klafki, Hans W., Stazi, Martina, Oberstein, Timo J., Ghiso, Jorge, Wiltfang, Jens, Bayer, Thomas A., Weggen, Sascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628465/ https://www.ncbi.nlm.nih.gov/pubmed/28978359 http://dx.doi.org/10.1186/s13195-017-0309-z

Ejemplares similares

Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia
por: Hüttenrauch, Melanie, et al.
Publicado: (2018)

Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer’s disease
por: Aichholzer, Freyja, et al.
Publicado: (2021)

Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models
por: Reinert, Jochim, et al.
Publicado: (2016)

N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease
por: Zampar, S., et al.
Publicado: (2020)

A Combination of Caffeine Supplementation and Enriched Environment in an Alzheimer’s Disease Mouse Model
por: Stazi, Martina, et al.
Publicado: (2023)

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease
por: Bayer, Thomas A., et al.
Publicado: (2014)

Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis
por: Stazi, Martina, et al.
Publicado: (2021)

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease
por: Shahpasand-Kroner, Hedieh, et al.
Publicado: (2018)

Neuron Loss in Transgenic Mouse Models of Alzheimer's Disease
por: Wirths, Oliver, et al.
Publicado: (2010)

Chronic Memantine Treatment Ameliorates Behavioral Deficits, Neuron Loss, and Impaired Neurogenesis in a Model of Alzheimer’s Disease
por: Stazi, Martina, et al.
Publicado: (2020)

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Matrix Development for the Detection of Phosphorylated Amyloid-β Peptides by MALDI-TOF-MS
por: Liepold, Thomas, et al.
Publicado: (2023)

N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
por: Rostagno, Agueda, et al.
Publicado: (2022)

Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions
por: Vogelgsang, Jonathan, et al.
Publicado: (2018)

Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model
por: Hüttenrauch, M, et al.
Publicado: (2016)

Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
por: Wirths, Oliver, et al.
Publicado: (2020)

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Physical Activity Ameliorates Impaired Hippocampal Neurogenesis in the Tg4-42 Mouse Model of Alzheimer’s Disease
por: Gerberding, Anna-Lina, et al.
Publicado: (2019)

Abundance of Aβ(5-x) like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer’s disease
por: Guzmán, Erika Avendaño, et al.
Publicado: (2014)

Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease
por: Hermann, Peter, et al.
Publicado: (2022)

Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay
por: Kraus, Inga, et al.
Publicado: (2015)

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease
por: Weggen, Sascha, et al.
Publicado: (2012)

Development and Technical Validation of an Immunoassay for the Detection of APP(669–711) (Aβ(−3–40)) in Biological Samples
por: Klafki, Hans W., et al.
Publicado: (2020)

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
por: Wirths, Oliver, et al.
Publicado: (2009)

Intracellular Accumulation of Amyloid-Beta – A Predictor for Synaptic Dysfunction and Neuron Loss in Alzheimer's Disease
por: Bayer, Thomas A., et al.
Publicado: (2010)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
por: Bader, Angelika Sabine, et al.
Publicado: (2023)

The Arctic AβPP mutation leads to Alzheimer’s disease pathology with highly variable topographic deposition of differentially truncated Aβ
por: Kalimo, Hannu, et al.
Publicado: (2013)

Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer’s Disease
por: Bulic, Bruno, et al.
Publicado: (2011)

N-Truncated Aβ Starting at Position Four—Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer’s Disease
por: Bayer, Thomas A.
Publicado: (2021)

The presubiculum is preserved from neurodegenerative changes in Alzheimer’s disease
por: Murray, Christina E., et al.
Publicado: (2018)

Synaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
por: Dietrich, Katharina, et al.
Publicado: (2018)

Meprin β knockout reduces brain Aβ levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimer’s disease
por: Marengo, Liana, et al.
Publicado: (2022)

Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease
por: Zhou, Yan, et al.
Publicado: (2018)

Transcriptomic profiling of sporadic Alzheimer’s disease patients
por: Caldwell, Andrew B., et al.
Publicado: (2022)

Blood Platelets in the Progression of Alzheimer’s Disease
por: Gowert, Nina S., et al.
Publicado: (2014)

Circulating immune complexes of Aβ and IgM in plasma of patients with Alzheimer’s disease
por: Marcello, Andrea, et al.
Publicado: (2009)

Microbiome-Mediated Upregulation of MicroRNA-146a in Sporadic Alzheimer’s Disease
por: Zhao, Yuhai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_abn3via3md0bo46j0vc38ljptq